{"doi":"10.1016/j.xpro.2025.103955","title":"Protocol for high-throughput viability screening and gene expression of human EndoC-βH5 β cells and pancreatic islets","abstract":"Viability assays allow the assessment of toxicity induced by any treatment of interest. Here, we present a protocol to evaluate cell viability in human EndoC-βH5 β cells and human pancreatic islets using a high-throughput fluorescence viability assay. We describe the steps for cell and islet culture, reagent dilution, viability assay preparation, and performance. The protocol is compatible with RNA isolation and gene expression analysis on the same cells, and we detail procedures for reagent washout and profiling gene expression. For complete details on the use and execution of this protocol, please refer to Rampazzo Morelli et al. 1 • Protocol to measure relative cell viability of EndoC-βH5 β cells and human islets • Instructions for culturing EndoC-βH5 cells and human islets for the viability assay • Steps for reagent dilution, viability assay setup, and performance • Guidance on reagent removal for gene expression analysis from the same cells Publisher’s note: Undertaking any experimental protocol requires adherence to local institutional guidelines for laboratory safety and ethics. Viability assays allow the assessment of toxicity induced by any treatment of interest. Here, we present a protocol to evaluate cell viability in human EndoC-βH5 β cells and human pancreatic islets using a high-throughput fluorescence viability assay. We describe the steps for cell and islet culture, reagent dilution, viability assay preparation, and performance. The protocol is compatible with RNA isolation and gene expression analysis on the same cells, and we detail procedures for reagent washout and profiling gene expression.","journal":"STAR Protocols","year":2025,"id":570562,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9502,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":7389,"name":"Peter J. Thompson","orcid":"0000-0002-6851-8899","position":1,"is_corresponding":false},{"id":1375665,"name":"Nayara Rampazzo Morelli","orcid":"0000-0001-7183-4668","position":0,"is_corresponding":true}],"reference_count":3,"raw_metadata":{"citation_network_status":"fetched"},"created_at":"2026-07-19T02:57:07.857542Z","pmid":"40682782","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}